The word is out that green, sustainable technology is good not only for the corporate image, but also for the bottom line. Around 2001, the first green chemistry programs began appearing at pharmaceutical companies, led by a groundbreaking multicenter program at Pfizer. Since then, pharmaceutical companies have been setting—and meeting—aggressive goals for reduction of energy usage, waste, and carbon footprint.
ONLINE EXCLUSIVE | JPS Update
Selected abstracts from recent issues of the Journal of Pharmaceutical Sciences, which is published by John Wiley & Sons on behalf of the American Pharmacists Association.
Synthesis and In Vitro Release of Adriamycin
Targeted Cancer Therapy with Novel High Drug-Loading Nanocrystals
For the first time, researchers from the Netherlands have identified the ingredient in honey that kills bacteria. Defensin-1, a protein that bees add to honey, possesses powerful antibacterial properties.
FROM OUR NEWSLETTER
Stay in the loop with our free, semi-monthly eNewsletter. Sign up today!
Sanofi-aventis, maker of the low molecular weight heparin product Lovenox (enoxaparin sodium), expressed reservations about the U.S. Food and Drug Administration’s (FDA) approval of a generic form of the drug last month.
Surplus could have safety, efficacy effects, agency says
A draft guidance issued this month by the U.S. Food and Drug Administration (FDA) calls for manufacturers of transdermal and transmucosal delivery systems to minimize the amount of drug left in these products at the end of the life cycle.
A technique using laser pulses to create microbubbles could allow selective injection of materials into single cells, according to researchers at Duke University.
